Can I start Depakote (valproic acid) for an 83‑year‑old patient with dementia who is already on quetiapine 25 mg twice daily, trazodone 50 mg nightly, and alprazolam 0.5 mg PRN?

I would not recommend adding Depakote to this 83-year-old patient with dementia.

Depakote (valproic acid) is likely ineffective for treating behavioral symptoms in dementia and carries significant risks in elderly patients, particularly when combined with other sedating medications like quetiapine, trazodone, and alprazolam.

Why Depakote Should Be Avoided

Evidence of Ineffectiveness

The evidence consistently demonstrates that valproate preparations do not work for agitation in dementia. A Cochrane systematic review found probably little or no effect on agitation scores (BPRS agitation factor: MD -0.67,95% CI -1.49 to 0.15) 1. Multiple studies measuring agitation with the Cohen-Mansfield Agitation Index showed no benefit 1. More recent systematic reviews confirm valproate is likely ineffective for behavioral and psychological symptoms of dementia 2.

Serious Safety Concerns in Elderly Patients with Dementia

The FDA label specifically warns about somnolence in the elderly with dementia 3. In a double-blind trial of elderly dementia patients (mean age 83 years—exactly your patient's age), valproate caused:

• Significantly higher somnolence compared to placebo
• Higher rates of dehydration
• Reduced nutritional intake and weight loss in approximately half of somnolent patients
• Significantly more discontinuations due to somnolence 3

Increased Adverse Events

Valproate-treated dementia patients experience twice the rate of adverse effects compared to placebo (OR 2.02,95% CI 1.30-3.14) 1. Common problems include:

• Sedation
• Gastrointestinal symptoms (nausea, vomiting, diarrhea)
• Urinary tract infections

There may also be a nearly 5-fold increased risk of serious adverse events (OR 4.77,95% CI 1.00-22.74), though this evidence is of very low quality 1.

Mortality Risk

A large VA study of 33,604 dementia patients found valproic acid carried mortality risk comparable to antipsychotics (relative risk 0.91,95% CI 0.78-1.06 compared to risperidone), with risk highest in the first 120 days 4.

Dangerous Polypharmacy Concerns

Your patient is already on three sedating medications:

• Quetiapine 25 mg BID (sedating atypical antipsychotic)
• Trazodone 50 mg nightly (sedating antidepressant)
• Alprazolam 0.5 mg PRN (benzodiazepine)

Adding Depakote would create a fourth sedating agent, dramatically increasing risks of:

• Falls and fractures
• Excessive sedation
• Dehydration
• Cognitive worsening
• Respiratory depression

Recent guidelines emphasize deprescribing in dementia patients with frailty, specifically recommending discontinuation of benzodiazepines when possible due to adverse effects 5. The 2014 expert panel on neuropsychiatric symptoms strongly advocates for medication review and reduction before adding new agents 6.

What to Do Instead

First: Optimize Current Regimen

Before adding anything, consider:

1. Assess if quetiapine is actually helping—if no clear benefit after 4 weeks at adequate dose, taper and discontinue 7
2. Discontinue or reduce alprazolam—benzodiazepines worsen cognition, increase fall risk, and can cause paradoxical agitation in 10% of dementia patients 8
3. Evaluate trazodone necessity—is sleep the primary issue or agitation?

Second: Address Underlying Causes

The 2016 APA guidelines emphasize assessing for modifiable contributors before adding medications 7:

• Pain (extremely common and undertreated in dementia)
• Infection (UTI, pneumonia)
• Constipation or urinary retention
• Environmental triggers (overstimulation, unmet needs)
• Medication side effects from current drugs

Third: Non-Pharmacological Interventions

The 2014 expert panel recommends a structured 4-step approach 6:

1. Describe the specific behaviors (frequency, triggers, timing)
2. Investigate underlying causes (pain, infection, unmet needs)
3. Create a person-centered care plan with caregiver education
4. Evaluate effectiveness before escalating to medications

Fourth: If Medication Truly Needed

If severe, dangerous agitation persists despite the above:

• Optimize quetiapine dosing (can go up to 200 mg BID per guidelines, though start low) 8
• Consider switching to risperidone if quetiapine ineffective (better evidence for agitation, though mortality risk exists) 7
• Never use haloperidol—highest mortality risk and least efficacy 4

Monitoring Requirements If You Disregard This Advice

If Depakote is started despite these recommendations, the FDA mandates 3:

• Start 125 mg BID (lower than standard due to age)
• Monitor closely for somnolence, dehydration, reduced food/fluid intake
• Check liver enzymes, platelets, PT/PTT
• Monitor valproate levels (target 40-90 mcg/mL, though even therapeutic levels showed no benefit in trials)
• Dose reductions or discontinuation required if decreased intake or excessive somnolence
• Increase doses more slowly than in younger patients

Bottom Line

Depakote has no proven benefit for dementia-related agitation, carries significant risks in 83-year-old patients, and would add to an already concerning medication burden. The 2002 guidelines listed it as an option 8, but subsequent high-quality evidence has definitively shown it doesn't work 1. Focus instead on deprescribing current medications, identifying treatable causes of agitation, and implementing non-pharmacological interventions.